Key Insights

Highlights

Success Rate

76% trial completion

Published Results

106 trials with published results (13%)

Research Maturity

323 completed trials (40% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

12.7%

103 terminated out of 813 trials

Success Rate

75.8%

-10.7% vs benchmark

Late-Stage Pipeline

0%

3 trials in Phase 3/4

Results Transparency

33%

106 of 323 completed with results

Key Signals

106 with results76% success103 terminated

Data Visualizations

Phase Distribution

809Total
Not Applicable (9)
Early P 1 (18)
P 1 (750)
P 2 (29)
P 3 (2)
P 4 (1)

Trial Status

Completed323
Recruiting189
Terminated103
Unknown80
Not Yet Recruiting58
Active Not Recruiting46

Trial Success Rate

75.8%

Benchmark: 86.5%

Based on 323 completed trials

Clinical Trials (813)

Showing 20 of 20 trials
NCT07545265Phase 1Not Yet RecruitingPrimary

SKB565 for Injection in Advanced Solid Tumors

NCT05067283Phase 1RecruitingPrimary

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

NCT07738679Phase 2Not Yet RecruitingPrimary

Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid Tumors

NCT06915753Phase 1Recruiting

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

NCT04058756Phase 1Active Not RecruitingPrimary

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

NCT06987058Phase 2Enrolling By InvitationPrimary

RVU120 Rollover Study

NCT07524348Phase 1RecruitingPrimary

A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

NCT06792552Phase 1RecruitingPrimary

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

NCT04222413Phase 1RecruitingPrimary

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT07042100Phase 1RecruitingPrimary

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

NCT06818643Phase 1RecruitingPrimary

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

NCT06445517Phase 1RecruitingPrimary

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

NCT07460375Phase 1RecruitingPrimary

A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

NCT07689812Not ApplicableNot Yet Recruiting

A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.

NCT05836324Phase 1Recruiting

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

NCT06719362Phase 1RecruitingPrimary

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

NCT06004245Phase 1RecruitingPrimary

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

NCT07172919Phase 2RecruitingPrimary

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

NCT05719558Phase 1RecruitingPrimary

A Study of ASP1002 in Adults for Treatment of Solid Tumors

NCT07551778Phase 1Not Yet Recruiting

Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors

Scroll to load more

Research Network

Activity Timeline